CeNeS Pharmaceuticals PLC
Compass House, Vision Park
Chivers Way
Histon
Cambridge
CB4 9ZR
Tel: 44-0-1223-266-466
Fax: 44-0-1223-266-467
Website: http://www.cenes.com/
16 articles about CeNeS Pharmaceuticals PLC
-
CeNeS Pharmaceuticals PLC Completes Preparations for Phase III Trial of M6G in US
12/7/2007
-
CeNeS Pharmaceuticals PLC Release: Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Statement
8/22/2007
-
CeNeS Pharmaceuticals PLC Licenses New Intravenous Anaesthetic to Ono Pharmaceutical Company, Ltd. in Japan
8/6/2007
-
Major New Review Supports the Broader Potential of CeNeS Pharmaceuticals PLC COMT Inhibitor Discovery Programme
7/3/2007
-
CeNeS Pharmaceuticals PLC Release: FDA Approves IND on Lead Product M6G
4/26/2007
-
CeNeS Pharmaceuticals PLC Files IND for Lead Product M6G
3/28/2007
-
CeNeS Pharmaceuticals PLC: Successful Phase III Results Announced On Lead Product M6G
2/20/2007
-
CeNeS Pharmaceuticals PLC Release: Placing To Raise £4.82M, Completion Of Recruitment For Phase III Trials Of M6G And Change Of Nominated Adviser
12/4/2006
-
Tripos Extends Its COMT Inhibitor Program With CeNeS Pharmaceuticals PLC
9/12/2006
-
ErgoMed Signs Co-Development Deal With CeNeS Pharmaceuticals PLC
7/13/2006
-
CeNeS Pharmaceuticals PLC Strengthens The Patent Portfolio For Its Lead Clinical Programme M6G (Morphine-6-Glucuronide)
6/7/2006
-
CeNeS Pharmaceuticals PLC Announces The Publication Of An Important Independent Review Of Its Lead Product, M6G
5/25/2006
-
CeNeS Pharmaceuticals PLC Announces Preliminary Results For The Year Ended 31 December 2005
4/10/2006
-
CeNeS Pharmaceuticals PLC Enters Collaboration With ErgoMed To Finalise Phase II Clinical Trial Plans For CNS 5161
3/7/2006
-
CeNeS Pharmaceuticals PLC Signs Deal To Strengthen Intellectual Property For Morphine-6-Glucuronide (M6G) Synthesis And Manufacture
3/6/2006
-
CeNeS Pharmaceuticals PLC Chairman Buys 500,000 Shares, CEO Buys 120,000 At 8p Each
12/16/2005